T
TREVI THERAPEUTICS INC
NASDAQ: TRVI (Trevi Therapeutics, Inc.)
Kemas kini terakhir: 6 jam lalu14.41
0.22 (1.55%)
| Penutupan Terdahulu | 14.19 |
| Buka | 14.00 |
| Jumlah Dagangan | 898,764 |
| Purata Dagangan (3B) | 1,489,047 |
| Modal Pasaran | 2,045,164,928 |
| Harga / Buku (P/B) | 10.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -0.450 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.96% |
| Nisbah Semasa (MRQ) | 15.38 |
| Aliran Tunai Operasi (OCF TTM) | -41.27 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -24.53 M |
| Pulangan Atas Aset (ROA TTM) | -34.41% |
| Pulangan Atas Ekuiti (ROE TTM) | -55.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Trevi Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
2.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 2.25 |
|
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.75% |
| % Dimiliki oleh Institusi | 79.20% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Eventide Asset Management, Llc | 31 Dec 2025 | 2,622,306 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 21.00 (HC Wainwright & Co., 45.73%) | Beli |
| Median | 20.00 (38.79%) | |
| Rendah | 19.00 (D. Boral Capital, 31.85%) | Beli |
| Purata | 20.00 (38.79%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 11.70 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| D. Boral Capital | 09 Mar 2026 | 19.00 (31.85%) | Beli | 11.70 |
| HC Wainwright & Co. | 09 Mar 2026 | 21.00 (45.73%) | Beli | 11.70 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |